Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517749 | 0.81 | TSHR (0.35) | MMP1MMP8MEN1KMT2AALDH1A1 | |
| SCHEMBL21764799 | 0.79 | LPAR3 (0.36) | MMP1MEN1KMT2AALDH1A1PLA2G2A | |
| SCHEMBL27907494 | 0.77 | ALDH1A1 (0.34) | MMP1MMP8MEN1KMT2AEPHX2 | |
| SCHEMBL21764714 | 0.76 | CYP3A4 (0.48) | ALDH1A1PLA2G2A | |
| SCHEMBL21764587 | 0.74 | LPAR3 (0.55) | PLA2G2A | |
| SCHEMBL19302945 | 0.74 | TSHR (0.40) | HSD17B10MMP1MMP8ALDH1A1TDP1 | |
| SCHEMBL1270333 | 0.73 | LPAR3 (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1173655 | 0.73 | ALDH1A1 (0.41) | MAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL21764797 | 0.73 | LPAR3 (0.58) | PLA2G2A | |
| SCHEMBL9258322 | 0.71 | ALDH1A1 (0.39) | MAPK1PKMMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | MAPK1 3744/4885PKM 3921/4885HSD17B10 3875/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | MAPK1 4662/4885PKM 1413/4885HSD17B10 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.